최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Archives of pharmacal research : a publication of the Pharmaceutical Society of Korea, v.27 no.12, 2004년, pp.1258 - 1262
Cho, Eun-Sook (College of Pharmacy, Sookmyung Women's University) , Yu, Ja-Heon (College of Pharmacy, Sookmyung Women's University) , Kim, Mi-Sun (College of Pharmacy, Sookmyung Women's University) , Yim, Mi-Jung (College of Pharmacy, Sookmyung Women's University)
Phosphodiesterase (PDE) 4 is an enzyme that degrades intracellular cAMP. In the present study, the effect of rolipram, a specific phosphodiesterase (PDE) 4 inhibitor, on osteoclast formation was investigated. Rolipram induced osteoclast formation in cocultures of mouse bone marrow cells and calvaria...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
Conti, M. and Jin, S. L., The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic. Acid Res. Mol. Biol., 63,1-38 (1999)
Essayan, D. M., Cyclic nucleotide phosphodiesterases. J. Allergy CIin. lmmunol., 108, 671-680 (2001)
Fu, Q., Jilka R. L., Manolagas, S. C., and O'Brien, C. A., Parathyroid hormone stimulates receptor activator of NF kappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response elementbinding protein. J. Biol. Chem., 277, 48868-48875 (2002)
Houslay, M. D. and Adams, D. R., PDE4 cAMP phosphodie sterases: modular enzymes that orchestrate signalling crosstalk, desensitization and compartmentalization. Biochem. J, 370, 1-18 (2003)
Houslay, M. D., Sullivan, M., and Bolger, G. B., The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. Adv. Pharmacol., 44, 225-342 (1998)
Kinoshita, T., Kobayashi, S., Ebara, S., Yoshimura, Y., Horiuchi, H., Tsutsumimoto, T., Wakabayashi, S., and Takaoka, K., Phosphodiesterase inhibitors, pentoxifylline and rolipram, increase bone mass mainly by promoting bone formation in normal mice. Bone, 27, 811-817 (2000)
Kondo, H., Guo, J., and Bringhurst, F. R., Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res., 17, 1667-1679 (2002)
Miyamoto, K., Waki, Y., Horita, T., Kasugai, S., and Ohya, K., Reduction of bone loss by denbufylline, an inhibitor of phosphodiesterase 4. Biochem. Pharmacol., 54, 613-617 (1997)
Suda, T., Takahashi, N., Udagawa, N., Jimi, E, Gillespie, M. T., and Martin, T. J., Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 20, 345-357 (1999)
Takahashi, N., Akatsu, T., Udagawa, N., Sasaki, T., Yamaguchi, A., Moseley, J. M., Martin, T. J., and Suda, T., Osteoblastic cells are involved in osteoclast formation. Endocrinology, 123, 2600-2602 (1988)
Takahashi, N., Udagawa, N., and Suda, T. A., New member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/ RANKL, regulates osteoclast differentiation and function. Biochem .Biophys. Res.Commun., 256, 449-455 (1999)
Tam, C. S., Heersche, J. N., Murray, T. M., and Parsons, J. A., Parathyroid hormone stimulates the bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology, 110, 506-512 (1982)
Tsutsumimoto, T., Wakabayashi, S., Kinoshita, T., Horiuchi, H., and Takaoka, K., A phosphodiesterase inhibitor, pentoxifylline, enhances the bone morphogenetic protein-4 (BMP-4)dependent differentiation of osteoprogenitor cells. Bone, 31, 396-401 (2002)
Vaananen, H. K., Zhao, H., Mulari, M., and Halleen, J. M., The cell biology of osteoclast function. J. Cell Sci., 113, 377-381 (2000)
Wakabayashi, S., Tsutsumimoto, T., Kawasaki, S., Kinoshita, T., Horiuchi, H., and Takaoka, K., Involvement of phosphodiesterase isozymes in osteoblastic differentiation. J Bone Miner. Res., 17, 249-56 (2002)
Waki, Y., Horita, T., Miyamoto, K., Ohya, K., and Kasugai, S., Effects of XT-44, a phosphodiesterase 4 inhibitor, in osteoblastgenesis and osteoclastgenesis in culture and its therapeutic effects in rat osteopenia models. Jpn. J Pharmacol., 79, 477-483 (1999)
Wong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett 3rd, F. S., Frankel, W. N., Lee, S. Y., and Choi, Y., TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun Nterminal kinase in T cells. J. Biol. Chem., 272, 25190-25194 (1997)
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
Free Access. 출판사/학술단체 등이 허락한 무료 공개 사이트를 통해 자유로운 이용이 가능한 논문
※ AI-Helper는 부적절한 답변을 할 수 있습니다.